Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$222.86
-0.1%
$171.73
$96.09
$234.29
$11.42B0.59703,084 shs281,529 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.97
+13.0%
$23.82
$10.75
$27.72
$12.90B1.694.94 million shs8.21 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$10.71
+7.2%
$15.79
$1.06
$24.28
$3.32B0.687.31 million shs3.60 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.49
+1.7%
$13.77
$12.77
$16.17
$11.26B0.272.17 million shs3.22 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+8.00%+20.57%+32.37%+20.22%+91.48%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.25%+3.83%-0.26%-5.69%+139.27%
Erasca, Inc. stock logo
ERAS
Erasca
-0.40%+0.91%-43.91%-11.12%+588.97%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-3.35%-5.43%-0.58%-5.25%-4.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$222.86
-0.1%
$171.73
$96.09
$234.29
$11.42B0.59703,084 shs281,529 shs
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$25.97
+13.0%
$23.82
$10.75
$27.72
$12.90B1.694.94 million shs8.21 million shs
Erasca, Inc. stock logo
ERAS
Erasca
$10.71
+7.2%
$15.79
$1.06
$24.28
$3.32B0.687.31 million shs3.60 million shs
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$13.49
+1.7%
$13.77
$12.77
$16.17
$11.26B0.272.17 million shs3.22 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
+8.00%+20.57%+32.37%+20.22%+91.48%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
+2.25%+3.83%-0.26%-5.69%+139.27%
Erasca, Inc. stock logo
ERAS
Erasca
-0.40%+0.91%-43.91%-11.12%+588.97%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
-3.35%-5.43%-0.58%-5.25%-4.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
2.90
Moderate Buy$251.2612.74% Upside
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
2.77
Moderate Buy$27.907.43% Upside
Erasca, Inc. stock logo
ERAS
Erasca
2.50
Moderate Buy$17.8866.90% Upside
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00
Hold$16.9025.32% Upside

Current Analyst Ratings Breakdown

Latest ERAS, RDY, ELAN, and AXSM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$242.00 ➝ $302.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$270.00 ➝ $290.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetEqual Weight$217.00 ➝ $242.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOverweight$225.00 ➝ $255.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$228.00 ➝ $310.00
5/5/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetOutperform$241.00 ➝ $246.00
5/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Set Price Target$280.00
5/4/2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
Boost Price TargetBuy$245.00 ➝ $260.00
4/27/2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
UpgradeSell (D)Sell (D+)
(Data available from 5/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
$638.50M17.95N/AN/A$1.75 per share127.35
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$4.72B2.74$2.68 per share9.70$13.18 per share1.97
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/A$1.05 per shareN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$3.81B2.95$1.04 per share12.93$4.73 per share2.85
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$183.17M-$3.69N/A39.94N/A-26.59%-246.90%-29.04%N/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
-$232M-$0.48N/A22.202.87-4.92%7.16%3.53%5/6/2026 (Estimated)
Erasca, Inc. stock logo
ERAS
Erasca
-$124.55M-$0.44N/AN/AN/AN/A-34.48%-28.74%5/12/2026 (Estimated)
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$663M$0.7717.5123.2520.7416.41%15.89%10.73%5/12/2026 (Estimated)

Latest ERAS, RDY, ELAN, and AXSM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2026Q1 2026
Erasca, Inc. stock logo
ERAS
Erasca
-$0.19N/AN/AN/AN/AN/A
5/12/2026Q4 25/26
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.09N/AN/AN/A$886.58 millionN/A
5/6/2026Q1 2026
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.34$0.40+$0.06$0.11$1.28 billion$1.37 billion
5/4/2026Q1 2026
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.85-$1.26-$0.41-$1.26$191.10 million$191.20 million
3/12/2026Q4 2025
Erasca, Inc. stock logo
ERAS
Erasca
-$0.11-$0.10+$0.01-$0.10N/AN/A
2/24/2026Q4 2025
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
$0.11$0.13+$0.02-$0.56$1.09 billion$1.14 billion
2/23/2026Q4 2025
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
-$0.70-$0.56+$0.14-$0.56$191.33 million$196.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
N/AN/AN/AN/AN/A
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
N/AN/AN/AN/AN/A
Erasca, Inc. stock logo
ERAS
Erasca
N/AN/AN/AN/AN/A
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
$0.070.52%+9.86%9.09%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
1.38
1.55
1.48
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
0.60
2.17
1.08
Erasca, Inc. stock logo
ERAS
Erasca
N/A
10.04
10.04
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
0.03
1.88
1.38

Institutional Ownership

CompanyInstitutional Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
81.49%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
97.48%
Erasca, Inc. stock logo
ERAS
Erasca
67.78%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
3.85%

Insider Ownership

CompanyInsider Ownership
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
20.60%
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
1.14%
Erasca, Inc. stock logo
ERAS
Erasca
14.40%
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
2.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Axsome Therapeutics, Inc. stock logo
AXSM
Axsome Therapeutics
38051.44 million40.84 millionOptionable
Elanco Animal Health Incorporated stock logo
ELAN
Elanco Animal Health
9,400497.17 million491.50 millionOptionable
Erasca, Inc. stock logo
ERAS
Erasca
120310.97 million266.19 millionOptionable
Dr. Reddy's Laboratories Ltd stock logo
RDY
Dr. Reddy's Laboratories
27,811834.65 million817.96 millionOptionable

Recent News About These Companies

Doctor Reddy's: Fiscal Q3 Earnings Snapshot
Dr. Reddy's Laboratories Ltd (RDY) Stock Forecasts

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Axsome Therapeutics stock logo

Axsome Therapeutics NASDAQ:AXSM

$222.86 -0.20 (-0.09%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Elanco Animal Health stock logo

Elanco Animal Health NYSE:ELAN

$25.97 +2.98 (+12.96%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Erasca stock logo

Erasca NASDAQ:ERAS

$10.71 +0.72 (+7.21%)
As of 03:32 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories stock logo

Dr. Reddy's Laboratories NYSE:RDY

$13.48 +0.23 (+1.70%)
As of 03:31 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.